/Dr. Ankur Srivastava
A novel two-step pathway to detect liver cirrhosis earlier
A novel two-step pathway to detect liver cirrhosis earlier
21 Nov 2019

Non-alcoholic fatty liver disease (NAFLD) affects 20%-30% of the global population and can lead to more severe conditions including advanced fibrosis and cirrhosis. In this video, Dr. Ankur Srivastava, Consultant Gastroenterologist and Hepatologist at Southmead Hospital, North Bristol Trust, discusses his two-step primary care pathway approach of utilizing non-invasive tests to reduce unnecessary referrals and improve detection of severe disease in patients with NAFLD. This work was recently published in the Journal of Hepatology1 in August 2019 along with a second publication in BMC Gastroenterology2 July 2019, focused on health economics, comparing the cost-effectiveness of using different non-invasive test strategies in patients with NAFLD.

Srivastava, A. et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019 Aug;71(2):371-378. doi: 10.1016/j.jhep.2019.03.033. Epub 2019 Apr 6.

Srivastava, A. et al. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterol 19, 122 (2019) doi:10.1186/s12876-019-1039-4

Related Scientists

Related Content